Corcept医疗

Corcept Therapeutics CORT: Guyer William buys 20k shares at $21.65, sells 20k at $40.87.

Corcept Therapeutics's 15min chart shows MACD Death Cross and Bearish Marubozu

Corcept Therapeutics

Corcept Therapeutics' Share Price Falls 45% Despite 71% Gain Over Three Years.

Corcept Therapeutics Investigated for Securities Law Violations Over Misleading Statements.

agilonhealth

Corcept Therapeutics Investigated for Securities Law Violations

Catalyst<ul> <li>Most analysts rate CORT Buy or Strong Buy, showing broad institutional optimism.</li> <li>The company maintains strong cash reserves relative to market value.</li> <li>Recent Bullish Engulfing and WR Oversold signals in late November and early December point to rebound momentum for CORT.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>At least one major firm maintains a Neutral rating, citing valuation concerns.</li></ul>

Key Factors

William Guyer, Corcept Therapeutics' Chief Development Officer, bought 20,000 shares at $21.65 and sold 20,000 shares at $40.87 on February 3, 2026.Corcept Therapeutics is under investigation for potential securities law violations related to misleading statements and failure to disclose information about its relacorilant drug application.Corcept Therapeutics received a Complete Response Letter from the FDA for its New Drug Application for relacorilant, impacting its shares and regulatory outlook.

Recent Updates

CORT News